Who are we?
Padra Serum Alborz is claimed to be the most prominent manufacturer of snake anti-venom and scorpion anti-venom serums in Iran. In 2017, the company was organized to process hyperimmune plasma-derived products.
Considering Iran’s demand for anti-venom, Padra Serum has set up the first plasma refinery plant to produce scorpion and snake anti-venom serums under cGMP guidelines.
Since 2020, Padra Serum has been known as an anti-venom provider in Iran’s pharmaceutical industry by supplying greater than 70% of the required anti-venom towards the Ministry of Health, Treatment and Medical Education.
Our Vision
Leading in the production of hyperimmune plasma-derived medicines in Iran.
Achieving foreign currency savings and reducing dependency on imported products.
Completing the national portfolio of plasma-derived therapeutics to fully meet patient needs across the country.
Reducing venom-related mortality and morbidity by over 50% across Iran, while supporting nations lacking antivenom production.
Minimizing the risk of transmission of endemic and emerging infectious diseases from other regions to Iranian consumers.
Our Trajectory
In early 2017:
The research and development process for snake and scorpion antivenoms was initiated.
Around the middle of 2017:
Following the completion of the R&D phase, the production scale-up process commenced and also, production line was designed in accordance with the validated purification method.
By the close of 2017:
The plasma fractionation site was successfully established within Padra Serum, and its production line was brought into operation.
2018:
GMP certificate was awarded to Padra Serum.
2019:
The clinical trial for ScoFab® has been completed.
Padra Serum obtained an official product authorization license from the Iranian Food and Drug Administration.
2021:
The clinical trial for SnaFab 5® has been completed.
The clinical trial for SnaFab 6® has been completed.
2022:
Included in the World Health Organization’s published list of antivenom manufacturers.
2023:
Padra Serum became the main provider of anti-venom serums by covering approximately over 70% of Iran’s market.
2024:
Padra Serum Alborz has undergone a WHO inspection.
2025:
Padra Serum’s Antisnake Venom Serums (SnaFab 6®) have been registered in the Republic of Iraq by having received marketing authorization from the Iraqi Ministry of Health.
Our Team
Chief Executive Officer
Dr. Reza Shahidi
Qualified Person
Dr. Saeedeh Mousavi
Production Manager
Dr. Ramin Masoudi
Quality Control Manager
Dr. Giti Poyanmehr
BD Manager
Dr. Niousha Khoshdast
Warehouse Manager
Mr. Morteza Baba
Financial Affairs Manager
Ms. Shirin Mohebi
Commercial Manager
Ms. Marjan Khalafi